GLP-1 receptor agonists are the most significant pharmacological development in metabolic medicine in decades. Semaglutide, tirzepatide, and the incoming triple agonist retatrutide have demonstrated weight loss outcomes that were previously unachievable without bariatric surgery — and they’re doing it by correcting the underlying metabolic signaling that drives obesity, insulin resistance, and appetite dysregulation.

But there’s a critical difference between getting a prescription from a telehealth app and receiving GLP-1 therapy as part of an integrated metabolic protocol. The drugs work. The question is whether you’re using them intelligently.

The Mechanism: What These Medications Actually Do

GLP-1 (glucagon-like peptide-1) is an incretin hormone produced in your gut in response to food intake. It signals your pancreas to release insulin, suppresses glucagon secretion, slows gastric emptying, and acts on hypothalamic receptors to reduce appetite. In metabolic dysfunction, this signaling is impaired.

Semaglutide is a GLP-1 receptor agonist — it mimics GLP-1 and activates the same pathways. In the STEP trials, participants on semaglutide 2.4 mg weekly lost an average of 15–17% of body weight over 68 weeks.

Tirzepatide is a dual GIP/GLP-1 receptor agonist — it activates both the GLP-1 and GIP (glucose-dependent insulinotropic polypeptide) receptors simultaneously. In the SURMOUNT-1 trial, participants on the highest dose lost an average of 21% of body weight over 72 weeks — the largest weight loss recorded for any obesity medication at the time.

Retatrutide is the next evolution: a triple hormone receptor agonist that activates GIP, GLP-1, and glucagon receptors in a single molecule. That glucagon component is what makes it different. Glucagon receptor activation increases energy expenditure and promotes hepatic lipid oxidation — your liver burns more fat for fuel. The result is a medication that reduces appetite, improves insulin signaling, and simultaneously ramps up your body’s energy output. In a Phase 2 trial published in The New England Journal of Medicine, participants on the highest dose of retatrutide lost an average of 24.2% of body weight over 48 weeks — and they hadn’t plateaued yet. The first Phase 3 results, reported in December 2025, showed 28.7% weight loss at the 12 mg dose over 68 weeks — an average of roughly 71 pounds — along with meaningful improvements in cardiovascular risk markers like non-HDL cholesterol, triglycerides, and systolic blood pressure.

Retatrutide is not yet FDA-approved. It’s still in Phase 3 clinical trials, with seven additional readouts expected through 2026. But the trajectory is clear: triple agonism appears to produce greater weight loss than dual or single receptor approaches, and the metabolic benefits extend well beyond the scale. We’re watching this closely.

All three medications work. Your provider selects based on your metabolic profile, tolerance, goals, and what’s currently available in our formulary.

The Problem Nobody Talks About: Lean Mass Loss

Here’s what the telehealth clinics won’t tell you. When you lose 20–28% of your body weight on one of these medications, not all of that is fat. Studies estimate that 25–40% of weight lost on GLP-1 therapy is lean mass — muscle, bone mineral density, and organ tissue.

Muscle mass is the single strongest predictor of all-cause mortality in aging adults. Losing it while losing fat is a Pyrrhic victory if your goal is longevity.

This is why metabolic therapy should never be prescribed in isolation. It must be paired with adequate protein intake (1 g per pound of lean body mass, minimum), structured resistance training, and regular body composition monitoring.

How We Do It at Longitude Life

At Longitude Life, GLP-1 and incretin-based therapy lives within the RESTORE pillar — and it’s always integrated with DECODE diagnostics and OPTIMIZE protocols.

Before Prescribing: We run a full metabolic panel: fasting insulin, HOMA-IR (a calculated measure of insulin resistance), HbA1c, fasting glucose, advanced lipid panel with particle size, inflammatory markers, thyroid panel, and hormone cascade. We also perform an InBody body composition scan to establish your baseline lean mass, fat mass, visceral fat, and hydration.

This tells us whether metabolic therapy is appropriate, which medication to start with, and what your muscle preservation baseline looks like.

The Protocol: Semaglutide or tirzepatide is prescribed based on your metabolic profile and titrated slowly — starting at the lowest dose and increasing over weeks based on tolerance and response. We dispense from our in-house formulary (compounded semaglutide is available), included in your monthly medication credit. As retatrutide completes its regulatory pathway and becomes available, we’ll evaluate it for patients who may benefit from the additional glucagon receptor activity — particularly those with significant insulin resistance, elevated liver fat, or who need greater metabolic support than current options provide.

Simultaneously, your provider coordinates with our clinical team on protein intake targets and, for members on the Strength Protocol add-on, with your ARX trainer to ensure training load preserves and builds lean mass during the weight loss phase.

Monitoring: InBody scans monthly. Lab reassessment at 90 days. We’re tracking not just the scale but the ratio of fat loss to lean mass loss. If lean mass is declining disproportionately, we adjust — increasing protein, modifying training load, adding creatine, or adjusting medication timing.

The Strength Protocol Connection

This is where Longitude Life’s integrated model creates an outcome no telehealth prescription can match.

The Strength Protocol (+$300/month) pairs ARX adaptive resistance training with your metabolic protocol. ARX machines deliver computer-controlled resistance that matches your output on every rep — maximum muscular recruitment in 20-minute sessions, twice per week. Your force output is tracked quantitatively, session to session.

When you’re losing weight on a GLP-1 or triple-agonist medication, the Strength Protocol ensures that weight is fat, not muscle. Your provider and trainer communicate directly. If your testosterone is optimizing, we push load. If your cortisol is elevated from caloric deficit, we adjust recovery. This is strength training inside a medical framework.

Who Should Consider Metabolic Therapy

GLP-1 and incretin-based medications are appropriate for adults with a BMI of 30+ (or 27+ with metabolic comorbidities like insulin resistance, type 2 diabetes, hypertension, or dyslipidemia). They’re also valuable for patients with documented insulin resistance (elevated HOMA-IR) even at lower BMIs.

They’re not appropriate as cosmetic weight loss for people at healthy body composition, and they’re not a substitute for addressing root causes — thyroid dysfunction, hormonal imbalance, sleep disorders, and chronic inflammation should all be evaluated and treated concurrently.

The Landscape: Single, Dual, and Triple Agonists

The science in this space is moving fast. Here’s an honest summary of where things stand:

Semaglutide (GLP-1): Well-established. FDA-approved for obesity and type 2 diabetes. Extensive safety data across large cardiovascular outcomes trials. This is the current standard — reliable, well-understood, and effective for most patients. Average weight loss: 15–17%.

Tirzepatide (GIP + GLP-1): Well-established. FDA-approved for both indications. Dual mechanism appears to produce greater weight loss and may offer advantages in insulin sensitization and triglyceride reduction. Average weight loss: ~21%.

Retatrutide (GIP + GLP-1 + Glucagon): Promising but still early. Not yet FDA-approved. Phase 2 and early Phase 3 data show the highest weight loss recorded for any obesity medication — up to 28.7% — with additional benefits to liver fat and cardiovascular markers. The glucagon component is what differentiates it, potentially increasing energy expenditure beyond what appetite suppression alone can achieve. A novel side effect — dysesthesia (altered skin sensation) — has been reported in up to ~21% of participants at the highest dose, generally mild and not leading to discontinuation. Seven additional Phase 3 trials are expected to report in 2026, and FDA approval is projected for 2027–2028 if results hold.

We’ll prescribe what the evidence supports, when it’s available, matched to your biology. No loyalty to any one molecule. Metabolism isn’t willpower. It’s biochemistry — and it responds to biochemical intervention.

Semaglutide, Tirzepatide, Retatrutide and the Metabolic Revolution